Ratings Aarti Drugs Limited NSE India S.E.

Equities

AARTIDRUGS

INE767A01016

Delayed NSE India S.E. Other stock markets 02:57:50 2024-05-08 am EDT			5-day change	1st Jan Change
478.5 ^INR	+0.51%		-4.45%	-2.19%

May. 06	Transcript : Aarti Drugs Limited, Q4 2024 Earnings Call, May 06, 2024
May. 03	Aarti Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company sustains low margins.
The firm trades with high earnings multiples: 25.45 times its 2024 earnings per share.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
AARTI DRUGS LIMITED	-2.19%	524M	-	-
ELI LILLY AND COMPANY	+33.43%	700B		C+
NOVO NORDISK A/S	+26.43%	569B		B
JOHNSON & JOHNSON	-5.12%	358B		C+
MERCK & CO., INC.	+19.59%	330B		B-
ABBVIE INC.	+4.89%	287B		C+
ASTRAZENECA PLC	+14.32%	236B		B+
NOVARTIS AG	+5.79%	202B		B-
ROCHE HOLDING AG	-9.49%	197B		A+
AMGEN INC.	+4.26%	161B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes